Iteration is not solving the opioid crisis, it’s time for transformation

ABSTRACT Opioid use disorder (OUD) produces exceedingly high rates of morbidity and mortality in the United States and throughout the world. Almost 90% of persons qualifying for treatment do not enter treatment and 72% of those who initiate treatment leave within 60 days. This Perspective posits that over the past decade our OUD treatment system has produced only small iterative gains in treatment access because, in part, it is founded in a series of top-down regulatory policies dating back more than 100 years. These policies prioritized restricting persons with OUD from having access to opioid agonists over empirical discovery of treatment best practice. It further suggests that for persons who are not already responding positively to our existing treatments, we may need to fundamentally transform care to enact true, meaningful change. Four potential considerations are outlined: expanding beyond long-acting opioids for treatment, embracing safe use as a viable therapeutic target, ending closed medication distribution systems, and partnering with our patients. The overarching aim of this discussion is to motivate broader thinking about new solutions for the patients for whom the existing strategies are not working and who may benefit from more transformative approaches. Though efforts to-date to expand existing treatment systems and find new ways to promote existing MOUDs have been important, these efforts have represented iterative changes. For us to meet our goal of substantially reducing opioid-related harms, it may be time to consider strategies that represent true transformation.

• Publication year

  2023

• Venue

  The American Journal of Drug and Alcohol Abuse

• Publication date

  2023-03-04

• Fields of study

  Medicine, Political Science

• Identifiers
  DOI 10.1080/00952990.2023.2170807PMID 36920881
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Office-based Methadone Prescribing for Opioid Use Disorder: The Canadian Model

  2022cited by this paper
• Investigating opioid preference to inform safe supply services: A cross sectional study.

  2022cited by this paper
• A Plea From People Who Use Drugs to Clinicians: New Ways to Initiate Buprenorphine are Urgently Needed in the Fentanyl Era.

  2022cited by this paper
• Opioid Use Disorder: Pernicious and Persistent.

  2022cited by this paper
• Prescribing safe supply: ethical considerations for clinicians

  2022cited by this paper
• Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019”

  2022cited by this paper
• Expanding access to medications for opioid use disorder through locally-initiated implementation

  2022cited by this paper
• A low-barrier, flexible safe supply program to prevent deaths from overdose

  2022cited by this paper
• "If I had them, I would use them every time": Perspectives on fentanyl test strip use from people who use drugs.

  2022cited by this paper
• Factors associated with 60-day adherence to “safer supply” opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency

  2022cited by this paper
• The Methadone Manifesto: Treatment Experiences and Policy Recommendations From Methadone Patient Activists.

  2022cited by this paper
• Evaluating the population-level effects of overdose prevention sites and supervised consumption sites in British Columbia, Canada: Controlled interrupted time series

  2022cited by this paper
• Implementation of Safe Supply Alternatives During Intersecting COVID-19 and Overdose Health Emergencies in British Columbia, Canada, 2021.

  2022cited by this paper
• Reddit discussions about buprenorphine associated precipitated withdrawal in the era of fentanyl

  2021cited by this paper
• Effectiveness of Policies for Addressing the US Opioid Epidemic: A Model-Based Analysis from the Stanford-Lancet Commission on the North American Opioid Crisis

  2021cited by this paper
• Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings

  2021cited by this paper
• Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic

  2021cited by this paper
• Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.

  2021cited by this paper
• Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort.

  2021cited by this paper
• Assessing patient information and decision-support needs in problematic alcohol use and co-occurring depression to inform shared decision-making interventions.

  2021cited by this paper
• Evaluation of fentanyl test strip distribution in two Mid-Atlantic syringe services programs.

  2021cited by this paper
• "The Times They Are a-Changin'": Addressing Common Misconceptions About the Role of Safe Supply in North America's Overdose Crisis.

  2021cited by this paper
• Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls — United States, 2019–2020

  2021cited by this paper
• Buprenorphine prescriber monthly patient caseloads: An examination of 6-year trajectories.

  2021cited by this paper
• Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review

  2021cited by this paper
• Auricular nerve stimulation using the NSS-2 BRIDGE device to reduce opioid requirement following laparoscopic Roux-en-Y gastric bypass.

  2021cited by this paper
• How Academic Medicine Can Help Confront the Opioid Crisis

  2021cited by this paper
• The Changing Opioid Crisis: development, challenges and opportunities

  2020cited by this paper
• Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D

  2020cited by this paper
• Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.

  2020cited by this paper
• Community Attitudes Toward Opioid Use Disorder and Medication for Opioid Use Disorder in a Rural Appalachian County.

  2020cited by this paper
• A fentanyl test strip intervention to reduce overdose risk among female sex workers who use drugs in Baltimore: Results from a pilot study.

  2020cited by this paper
• Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.

  2020cited by this paper
• Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders.

  2020cited by this paper
• Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder

  2020cited by this paper
• Bacterial and Fungal Infections in Persons Who Inject Drugs — Western New York, 2017

  2019cited by this paper
• Methadone Matters: What the United States Can Learn from the Global Effort to Treat Opioid Addiction

  2019cited by this paper
• The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis.

  2019cited by this paper
• "Everything is not right anymore": Buprenorphine experiences in an era of illicit fentanyl.

  2019cited by this paper
• Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.

  2018cited by this paper
• Extended‐release injectable naltrexone for opioid use disorder: a systematic review

  2018cited by this paper
• Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial

  2017cited by this paper
• Harm reduction principles for healthcare settings

  2017cited by this paper
• Does evidence support supervised injection sites?

  2017cited by this paper
• Patient Preferences and Shared Decision Making in the Treatment of Substance Use Disorders: A Systematic Review of the Literature

  2016cited by this paper
• Trends in Methadone Distribution for Pain Treatment, Methadone Diversion, and Overdose Deaths - United States, 2002-2014.

  2016cited by this paper
• Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.

  2016cited by this paper
• Hydromorphone Compared With Diacetylmorphine for Long-term Opioid Dependence: A Randomized Clinical Trial.

  2016cited by this paper
• OF THE UNITED STATES

  2015cited by this paper
• Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy.

  2015cited by this paper
• The untapped potential of office-based buprenorphine treatment.

  2015cited by this paper
• National and State Treatment Need and Capacity for Opioid Agonist Medication-Assisted Treatment.

  2015cited by this paper
• Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment

  2012cited by this paper
• Potency ratio of hydromorphone and diacetylmorphine in substitution treatment for long-term opioid dependency.

  2011cited by this paper
• Double-blind injectable hydromorphone versus diacetylmorphine for the treatment of opioid dependence: a pilot study.

  2010cited by this paper
• Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial.

  2010cited by this paper
• Quality of life under maintenance treatment with heroin versus methadone in patients with opioid dependence.

  2010cited by this paper
• Diacetylmorphine versus methadone for the treatment of opioid addiction.

  2009cited by this paper
• Scientific and political challenges in North America's first randomized controlled trial of heroin-assisted treatment for severe heroin addiction: Rationale and design of the NAOMI study

  2009cited by this paper
• THE NARCOTIC FARM: THE RISE AND FALL OF AMERICA'S FIRST PRISON FOR DRUG ADDICTS

  2008cited by this paper
• Bioavailabilities of rectal and oral methadone in healthy subjects.

  2004cited by this paper
• Buprenorphine: how to use it right.

  2003cited by this paper
• National Institute of Justice

  2000cited by this paper
• Steady‐state pharmacokinetics and pharmacodynamics in methadone maintenance patients: Comparison of those who do and do not experience withdrawal and concentration‐effect relationships

  1999cited by this paper
• Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain

  1987cited by this paper
• Drug Laws and Drug Law Enforcement

  1986cited by this paper
• Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

  1978cited by this paper
• LONG‐TERM OUTCOME OF PATIENTS TREATED WITH METHADONE MAINTENANCE *

  1978cited by this paper
• Methadone maintenance treatment. Five years later--where are they now?

  1974cited by this paper
• An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction.

  1974cited by this paper
• Rating the presence and severity of opiate dependence

  1974cited by this paper
• A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

  1965cited by this paper
• The addiction liability of methadon (amidone, dolophine, 10820) and its use in the treatment of the morphine abstinence syndrome.

  1949cited by this paper
• The addiction liability of some drugs of the methadon series.

  1948cited by this paper
• The action of 1,1-diphenyl-1 (dimethylaminoisopropyl) butanone-2, a potent analgesic agent.

  1946cited by this paper
• The action of 1,1-diphenyl-1-(dimethylaminoisopropyl)-butanone-2, a potent analgesic agent.

  1946cited by this paper
• The Narcotic Farm

  year unknowncited by this paper

• Key-Informant Perspectives On Pharmacy-Based Methadone Treatment For Opioid Use Disorder In The US.

  2025cites this paper
• “From an HCV and HIV point of view, it's been remarkable”: A qualitative study about using prescribed safer supply to support people who use drugs along the HIV and HCV prevention and treatment cascades in Ontario, Canada

  2025cites this paper
• Perspectives on prescribed safer supply programs among people who inject drugs in Baltimore, Maryland: A mixed methods study among individuals highly affected by drug toxicity.

  2025cites this paper
• Starting Buprenorphine in Outpatient Settings Using a High-Dose Approach

  2025cites this paper
• Perspectives on Diversion of Medications From Safer Opioid Supply Programs

  2024cites this paper
• An interrupted time series analysis of fentanyl, naloxone, and opioid-involved deaths in five counties in Eastern Missouri.

  2024cites this paper
• Addiction Physician Specialty Training: How Does the USA Compare with Europe?

  2024cites this paper